Overview

A Study to Evaluate the Long-Term Safety of MEDI-545 in Adult Participants With Systemic Lupus Erythematosus or Myositis

Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to assess the safety and tolerability of sifalimumab in adult participants with active systemic lupus erythematosus (SLE) or active dermatomyositis (DM) or polymyositis (PM) who participated in the following clinical studies: MI-CP151, MI-CP152, or MI-CP179.
Phase:
Phase 2
Details
Lead Sponsor:
MedImmune LLC
Collaborator:
PPD
Treatments:
Antibodies, Monoclonal
Sifalimumab